Altering fibrotic and rejection responses using biomaterial systems

使用生物材料系统改变纤维化和排斥反应

• 批准号: 298472-2011
• 负责人: Jones, Kim
• 金额: $ 1.53万
• 依托单位: McMaster University
• 依托单位国家: 加拿大
• 项目类别: Discovery Grants Program - Individual
• 财政年份: 2012
• 资助国家: 加拿大
• 起止时间: 2012-01-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=509806
• 关键词: Altering; fibrotic; rejection; responses; using

From the established (e.g. stitches) to the futuristic (e.g. tissue-engineered constructs), polymers have found diverse applications as implanted biomaterials. Yet, their utility is limited by the accumulation of fibrous tissue that inevitably occurs and accompanying immune responses. The long-term objective of the proposed research program is to design biomaterial systems that minimise fibrosis and allogeneic rejection. In order to accomplish these goals, we have two major aims within the five year duration of the grant. 1) Using a model biomaterial, we will deliver candidate anti-fibrotic drugs to decrease local scarring responses. 2) By delivering key compounds from the biomaterial, we will induce tolerogenic cells that reduce allogeneic rejection. Creation of biologically active "combination" devices is relatively recent and has been driven primarily by tissue engineering. However (and despite more complex regulatory issues), the field of implanted devices will also benefit greatly from biomaterials that actively direct responses away from fibrosis and rejection.

从传统的(例如缝合)到未来的(例如组织工程构建)，聚合物作为植入性生物材料得到了广泛的应用。然而，它们的用途受到不可避免地出现的纤维组织积累和伴随免疫反应的限制。拟议研究计划的长期目标是设计将纤维化和同种异体排斥反应降至最低的生物材料系统。为了实现这些目标，我们在赠款的五年期限内有两个主要目标。1)使用模型生物材料，我们将提供候选的抗纤维化药物来减少局部瘢痕反应。2)通过输送生物材料中的关键化合物，我们将诱导产生耐受的细胞，以减少同种异体排斥反应。创造具有生物活性的“组合”装置是相对较新的，主要是由组织工程驱动的。然而(尽管存在更复杂的监管问题)，植入设备领域也将从积极引导反应远离纤维化和排斥的生物材料中受益匪浅。